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Abstract
Background: To investigate the significance of monitoring the levels of the serum squamous cell carcinoma
antigen (SCC-Ag) for the detection of recurrent disease in patients with cervical cancer treated by concurrent
chemoradiotherapy.
Methods: The records of 112 patients with cervical cancer were reviewed. Serum SCC-Ag levels were measured at
regular follow-up visits. A SCC-Ag level of 2 ng/mL was considered the upper limit of normal. Biochemical failure
was defined as two consecutively increasing SCC-Ag values above normal. Recurrent disease was confirmed by
histologic and radiographic studies.
Results: Eighteen patients (16%) developed recurrent disease. Sixteen patients had initially elevated SCC-Ag, post-
treatment normalization of SCC-Ag, and tumor recurrence. The SCC-Ag difference (ΔSCC-Ag), defined as the
difference between the last value after two consecutively increases above normal and the value immediately
before the elevation, had good clinical performance in predicting cancer recurrence. The cutoff value of ΔSCC-Ag
was 0.95 ng/mL.
Conclusions: SCC-Ag is a relatively good method for the detection of disease recurrence in patients with cervical
cancer who were treated by concurrent chemoradiotherapy.
Background
Radiotherapy has maintained its place as the cornerstone
of therapy for many decades for uterine cervical cancer.
Recently, the results of several randomized trials have
recommended the concomitant administration of che-
motherapy and radiotherapy as a standard treatment for
patients with locally advanced cervical cancer [1-3].
Although this combination treatment plays a role in
improving disease control, many patients suffer from
tumor recurrence during the follow-up period. Therefore,
the identification of prognostic factors associated with dis-
ease course and outcome following chemoradiotherapy
may help to guide the development of more effective treat-
ments and prevent tumor recurrence.
Over the past decade, several serum markers have been
investigated to search for additional prognostic para-
meters that could be used, to monitor the treatment
response, and detect the recurrence in patients with cer-
vical cancer. In particular, the squamous cell carcinoma
antigen (SCC-Ag) is the most commonly used tumor
marker for cervical cancer. SCC-Ag is a sub-fraction of
the tumor antigen TA-4, a 48 kDa glycoprotein first
isolated by Kato and Torigoe [4]. This antigen is present
in normal cervical epithelium, but has higher expression
in cervical neoplasms [5]. With the development of a sen-
sitive radioimmunoassay, this marker can be readily
detected in the serum and is now considered a valuable
tool for monitoring cervical cancer. Serum SCC-Ag levels
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correlate with the extent of disease [6-8], response to
radiotherapy [9], response to chemotherapy [10,11], and
can be used to predict survival and tumor recurrence
during follow-up [12-16]. Several studies have reported
the use of serial SCC-Ag data for post-therapeutic moni-
toring. In these reports, 70-86% of cervical cancer
patients with recurrent disease had elevated SCC-Ag
levels at some time during follow-up [7,8,11,14,16]. How-
ever, few studies have focused on cervical cancer patients
treated by concurrent chemoradiotherapy (CCRT), which
is now considered the standard treatment for locally
advanced cervical cancer.
In the present study, we investigated the potential use
of SCC-Ag as a marker for predicting tumor recurrence
in uterine cervical cancer patients treated with CCRT.
Methods
Between July 2001 and February 2004, 124 previously
untreated women with the International Federation of
Gynecology and Obstetrics (FIGO) stage IB-IV uterine
cervical cancer were entered in a CCRT protocol at the
National Cancer Center (Goyang, Gyeonggi, Republic of
Korea). Twelve cases that lacked regular SCC-Ag deter-
minations in the follow-up period were excluded from
the study. The pre-treatment evaluation consisted of a
complete medical history, physical examination, full
blood counts, biochemical profile, serum SCC-Ag, chest
radiography, intravenous pyelogram, cystoscopy, recto-
sigmoidoscopy, magnetic resonance imaging (MRI) or
computed tomography (CT) scan, and/or [18F]-flouro-
2-deoxy-D-glucose positron emission tomography
(FDG-PET). Written informed consent was obtained
from all the patients.
All patients were given external beam radiotherapy
(EBRT) with 15 MV X-rays from a linear accelerator
(Varian Clinac 2100CD; Varian, Palo Alto, CA, USA).
EBRT was administered to the whole pelvic region using
a four-field box technique or parallel opposed anterior-
posterior beams. The radiation field included the pri-
mary tumor, uterus, paracervical, parametrial and utero-
sacral regions, and the pelvic lymph nodes. The para-
aortic lymph nodes were also included if metastasis was
diagnosed during pre-treatment imaging study. The
radiation dose administered to the whole pelvis was
41.4-45 Gy (median 45 Gy), given in daily doses of 1.8
Gy, five fractions per week. An additional boost of 5.4-
21.4 Gy (median 10 Gy) was given to the gross residual
tumor and involved the parametrium without any mid-
line shielding. The dose to the para-aortic area was 45
Gy, with or without an additional booster dose of 10
Gy. Intracavitary brachytherapy was administered twice
weekly. Fletcher-Suit afterloading applicators were used
for high-dose-rate brachytherapy with an Iridium-192
source (Microselectron®; Nucletron, Veenendaal, The
Netherlands). The brachytherapy dose for each insertion
was 4 or 5 Gy at point A, and the total dose of
brachytherapy was 24-35 Gy (median 24 Gy). All
patients also were given concurrent chemotherapy,
which consisted of weekly doses of 40 mg/m2 i.v. cispla-
tin for four to six cycles.
After completion of CCRT, all patients were given
clinical examinations and assayed for serum SCC-Ag
during the follow-up visits. A radiation oncologist and a
gynecologist followed the patients for one month after
treatment, then every three months for the first two
years, and every 3-6 months thereafter. The follow-up
intervals varied for patients suspected of having recur-
rent disease, based on individual situations. Patients
with suspicious symptoms, such as signs at the physical
examination or an elevated serum SCC-Ag level during
follow-up periods, were given additional tests (histologi-
cal examination, abdomino-pelvic CT, pelvic MRI, FDG-
PET, etc.) to confirm the presence of recurrent diseases.
Serum SCC-Ag levels were measured using an immu-
noradiometric assay with a commercially available kit
(SCC-RIABEAD; SRL Inc., Tokyo, Japan). A measure-
ment of 2 ng/mL was considered the upper limit of nor-
mal. Biochemical failure was defined as two consecutively
increasing SCC-Ag values above the normal limits. For
further statistical analysis, after two consecutive elevated
SCC-Ag readings, the delta (Δ) SCC-Ag was defined as
the difference between the final value and the value
immediately before the elevation.
Logistic regression analysis was used to estimate the
probability of tumor recurrence from ΔSCC-Ag.
P values less than 0.05 were considered significant.
A receiver operating characteristic (ROC) curve was
used to define the optimal cutoff point for the SCC-Ag
values relative to the probability of a recurrence.
Results
Table 1 shows the demographic and clinical characteris-
tics of the 112 enrolled patients. At diagnosis, 77 patients
had elevated serum SCC-Ag, corresponding to an overall
pre-treatment sensitivity of 68.8% (77/112). Most patients
(96.1%) had normalized SCC-Ag levels at one month
after completion of CCRT. The median follow-up dura-
tion was 39 months (range, 16 - 55 months). Figure 1
shows the follow-up results.
After completion of CCRT, 18 patients (16%) experi-
enced tumor recurrence during the follow-up period.
Among these 18 patients, 11 had post-treatment SCC-
Ag elevations (biochemical failure) before the appear-
ance of clinically evident disease with a median
lead-time of 2 months (range, 1 - 15 months). An analy-
sis of all patients (n = 112) indicated that the sensitivity
and specificity of elevated post-treatment SCC-Ag levels
in association with recurrent disease were 61.1% and
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97.9%, respectively. For patients with elevated pre-treat-
ment SCC-Ag only (n = 77), these values were similar
(Table 2).
Next, we performed logistic regression of all patients
(n = 112) to estimate the probability of tumor recur-
rence based on ΔSCC-Ag measurements. Our results
indicate that ΔSCC-Ag was a significant predictor of
tumor recurrence (p = 0.001). Then, we performed
ROC analysis of ΔSCC-Ag to determine the optimal
levels for predicting the probability of tumor recur-
rence (Figure 2). The area under the ROC curve of
ΔSCC-Ag, which is considered to indicate the accuracy
of the test, was 0.78. The predictability of recurrence
was analyzed for patients who had an increase in the
level of pre-treatment SCC-Ag (n = 77). Logistic
regression analysis also indicated that ΔSCC-Ag was a
significant predictor of tumor recurrence (p = 0.002).
Figure 3 shows the ROC curve for ΔSCC-Ag in
patients with elevated pre-treatment SCC-Ag (n = 77).
These results indicate the area under the ROC curve
of ΔSCC-Ag was 0.83 and that a ΔSCC-Ag value of
0.95 ng/mL was the optimal cutoff level for prediction
of tumor recurrence. These mean that the true positive
and false positive rates of tumor recurrence were 75%
and 11% (respectively) when the difference between
the last value after two consecutive increases above
normal and the value immediately before the elevation
was 0.95 ng/mL.





FIGO stage – No. (%)




Histology – No. (%)
Squamous cell carcinoma 102 (91.1)
Adenocarcinoma 7 ( 6.2)
Adenosquamous cell carcinoma 3 ( 2.7)
Pelvic lymph node* – No. (%)
Positive 61 (54.5)
Negative 51 (45.5)
Tumor diameter – No. (%)
Range (cm) 1-10
≤4 cm 65 (58.0)
>4 cm 47 (42.0)
Abbreviations: FIGO = International Federation of Gynecology and Obstetrics.
* Pelvic lymph node status was diagnosed by imaging study.
Figure 1 A diagram of the follow-up results and the change in the SCC-Ag values in all patients.* Elevated serum SCC-Ag level means a
biochemical failure that is defined as two consecutively increasing tumor marker values above the normal limits, † No evidence of disease.
Table 2 Sensitivity, specificity, positive predictive value,
and negative predictive value of the tumor maker for
predicting a recurrence in all patients* and in patients
with elevated pretreatment tumor marker†
SCC-Ag (n = 112)* SCC-Ag (n = 77)†
Sensitivity 11/18 (61.1%) 11/16 (68.8%)
Specificity 92/94 (97.9%) 59/61 (96.7%)
PPV 11/13 (84.6%) 11/13 (84.6%)
NPV 92/99 (92.9%) 59/64 (92.2%)
Abbreviations: SCC-Ag = squamous cell carcinoma antigen; PPV = positive
predictive value; NPV = negative predictive value.
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Figure 2 Receiver operating characteristic curve for ΔSCC-Ag in predicting the probability of a recurrence in all patients.
Figure 3 Receiver operating characteristic curve for ΔSCC-Ag in predicting the probability of a recurrence in patients with elevated
pre-treatment tumor markers.
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Discussion
Our analysis of cervical cancer patients treated with
CCRT indicated that the sensitivity and specificity of
two consecutive increases in serum SCC-Ag for predict-
ing tumor recurrence were 61.1% and 97.9%, respec-
tively. These results are comparable to previously
reported results. For example, several studies of cervical
cancer patients showed that an elevated serum SCC-Ag
level was associated with 70-92% rate of recurrent
tumors [8,11,14-19]; in addition, the specificity of SCC-
Ag during the follow-up period was quite high, varying
from 95 to 98% [7,16,20]. According to our ROC analy-
sis, the area under the ROC curve indicated the ΔSCC-
Ag was 0.83 for patients who had elevated pre-treatment
SCC-Ag. Therefore, our results indicate that ΔSCC-Ag
had good clinical performance in detection of recurrent
disease.
As described above, we defined biochemical failure as
two consecutive SCC-Ag values above normal. There
are no standard criteria used to define biochemical fail-
ure in cervical cancer, and many previous studies have
simply defined failure as an increase of tumor markers
above normal. However, Duk et al. [20] reported that
the predictive value of a single elevation of serum SCC-
Ag level for early detection of recurrence was only
48.6%, but that the predictive value was 76% when two
consecutive elevated serum SCC-Ag levels were used.
Furthermore, they reported that serum SCC-Ag in the
second sample was considerably higher in patients who
had tumor relapse than in those with no evidence of
relapse. Similarly, 10 of our patients had only once
instance of elevated serum SCC-Ag, with normalization
at subsequent follow-ups. None of these 10 patients had
any evidence of disease at the final follow-up. Therefore,
we suggest use of additional measurement of SCC-Ag in
patients who have a single SCC-Ag elevation above the
normal limits. The use of sequential serum determina-
tions appears to increase the sensitivity and specificity of
serum SCC-Ag in predicting tumor recurrence.
The results reported here and those of others indicate
that routine surveillance of serum SCC-Ag during fol-
low-up can be used to predict tumor recurrence, but it
is unclear if the early detection of recurrence will lead
to better survival. The major aim of follow-up surveil-
lance in cervical cancer is the early recognition of a
recurrence, based on the presumption that early detec-
tion of tumor recurrence may allow effective salvage
therapy [18]. However, the clinical relevance of detecting
early recurrence of cervical cancer is controversial. Esa-
jas et al. [18] showed that routine assessment of serum
SCC-Ag in follow-up resulted in the earlier detection of
a recurrence in a small proportion of patients, but did
not appear to contribute to better survival. Chan et al.
[17] reported similar results, in that the addition of
SCC-Ag monitoring provided no advantage over a regu-
lar follow-up with a clinical examination. They con-
cluded that posttreatment SCC-Ag monitoring was not
cost-effective because there was no curative treatment
for distant spread of disease. Other studies, however,
have suggested that follow-up SCC-Ag measurements
may improve survival. Chou et al. [21] studied the clini-
cal features of isolated para-aortic lymph node recur-
rence after definitive radiotherapy and reported a good
correlation between lower SCC-Ag levels (SCC-Ag ≤4
ng/mL) at recurrence and disease-free survival. They
concluded that periodic surveillance with this tumor
marker and imaging studies allowed the early detection
and implementation of salvage therapy. Forni et al. [22]
reported that a simplified diagnostic approach that
included the SCC-Ag assay and a gynecologic examina-
tion allowed early detection of cervical cancer recur-
rence with a very favorable cost-effective profile.
Moreover, other recent studies reported that the use of
FDG-PET in patients with asymptomatic SCC-Ag eleva-
tion allowed an earlier diagnosis of recurrence, with pro-
mising effects on survival [23,24]. Therefore, further
study will be needed to confirm the value of routine
surveillance of SCC-Ag in improving survival rate from
recurrent cervical cancer after earlier detection.
Conclusions
In summary, measurement of ΔSCC-Ag provided good
clinical performance in the detection of recurrent uter-
ine cervical cancer following CCRT. We suggest that
clinicians consider performing routine measurement of
SCC-Ag during the follow-up of such patient. However,
our results should be interpreted with some caution,
because our overall recurrence rate was very low and
the follow-up period was relatively short. Therefore, a
more comprehensive, large-scale study should be
performed to confirm our results.
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